Vytorin Captures 2% Of New Prescriptions In Cholesterol Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck/Schering’s fixed-dose combination is ahead of AstraZeneca’s Crestor at a similar time during its launch, Schering-Plough says. Schering is also pleased with Vytorin’s level of managed care access.
You may also be interested in...
Merck/Schering-Plough Initiate Vytorin Acute Coronary Syndrome Trial
The two-year, 10,000-patient IMPROVE IT study will evaluate the Zetia/Zocor combination's morbidity/mortality risk reduction compared to Zocor alone. The trial will compare Vytorin 10 mg/40 mg to Zocor 40 mg in patients with acute coronary syndrome.
Merck/Schering-Plough Initiate Vytorin Acute Coronary Syndrome Trial
The two-year, 10,000-patient IMPROVE IT study will evaluate the Zetia/Zocor combination's morbidity/mortality risk reduction compared to Zocor alone. The trial will compare Vytorin 10 mg/40 mg to Zocor 40 mg in patients with acute coronary syndrome.
Vioxx Withdrawal Costs Merck Over $700 Mil. In Third Quarter
Impact of COX-2 inhibitor withdrawal reduces Merck’s quarterly earnings by over $550 mil. Merck reaffirms guidance for its major franchises, but Zocor sales are down for the quarter.